Search

Protagonist Therapeutics Inc

Cerrado

SectorSanidad

155.05 2.44

Resumen

Variación precio

24h

Actual

Mínimo

150.82

Máximo

155.38

Métricas clave

By Trading Economics

Ingresos

159M

163M

Ventas

157M

213M

P/B

Media del Sector

140.187

57.002

BPA

2.29

Margen de beneficios

76.285

Empleados

141

EBITDA

162M

165M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+7.28% upside

Dividendos

By Acuity

Próximas Ganancias

4 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.2B

9.7B

Apertura anterior

152.61

Cierre anterior

155.05

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

163 / 340 Clasificación en Healthcare

Protagonist Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 ago 2026, 22:36 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, remaining above their 20-day moving average and near the upper end of their one-month range.

13 ago 2026, 20:06 UTC

Correlated Moves
News
Social Media

Protagonist Therapeutics shares are lower amid insider selling concerns following CEO Dinesh V. Patel's recent stock transactions. The decline reflects broader sector trends.

12 ago 2026, 23:31 UTC

Social Media

Protagonist Therapeutics Inc gains after-market, reaching a high above Wednesday's close. Investor interest grows amid social media discussions on increasing positions.

11 ago 2026, 23:01 UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement amid earlier volatility and fluctuations.

10 ago 2026, 23:46 UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, with notable strength above the 20-day moving average and near the upper end of its one-month range.

6 ago 2026, 19:52 UTC

Social Media
News

Protagonist Therapeutics shares rise following multiple price target upgrades, including Citi's increase to $175, amid positive sentiment on drug approvals and pharmacokinetic data.

5 ago 2026, 22:02 UTC

News

Protagonist Therapeutics reports Q2 net income of $162.8 million, up from a loss last year. Shares are higher in after-market trading following the results.

4 ago 2026, 21:03 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, supported by their position above the 20-day moving average. No specific news was identified.

3 ago 2026, 19:36 UTC

Protagonist Therapeutics Inc shares are lower today, continuing a decline since Friday. The stock is near the lower end of its one-month range.

31 jul 2026, 19:36 UTC

Correlated Moves

Protagonist Therapeutics Inc is lower today amid broader weakness in the Biotechnology sector. Earlier in the session, shares pulled back from a high.

30 jul 2026, 21:02 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, amid notable volatility and significant price swings since Thursday's close.

29 jul 2026, 19:43 UTC

Macro Event

Protagonist Therapeutics Inc shares are lower amid market volatility following the Federal Reserve's decision to maintain interest rates, reflecting broader uncertainty.

28 jul 2026, 21:01 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, maintaining a notable gain since Tuesday's close, despite no specific news identified.

27 jul 2026, 20:02 UTC

Social Media

Protagonist Therapeutics shares are lower despite Jefferies raising its price target to $171 and Cowen increasing its peak royalty revenue forecast to $1.4 billion.

22 jul 2026, 19:42 UTC

News

Protagonist Therapeutics Inc is trading lower today, continuing a decline since Tuesday amid rising crude oil prices and market tensions related to Iran.

21 jul 2026, 19:06 UTC

Protagonist Therapeutics Inc shares are higher today, continuing an upward trend since Monday's close, supported by gains in the semiconductor sector.

20 jul 2026, 19:41 UTC

News
Social Media

Protagonist Therapeutics shares are lower as analysts raise price targets and revenue forecasts ahead of Q2 earnings, despite a noted 0% probability of success for PN-881.

Comparación entre iguales

Cambio de precio

Protagonist Therapeutics Inc previsión

Precio Objetivo

By TipRanks

7.28% repunte

Estimación a 12 Meses

Media 162.45 USD  7.28%

Máximo 186 USD

Mínimo 121 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Protagonist Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

11

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

163 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
help-icon Live chat